NCI-COG PEDIATRIC MATCH (MOLECULAR ANALYSIS FOR THERAPY CHOICE)- PHASE 2 SUBPROTOCOL OF LOXO-101 (LAROTRECTINIB) IN PATIENTS WITH TUMORS HARBORING ACTIONABLE NTRK FUSIONS
Categories (click each to see list of all clinical trials associated with that category): Pediatric (PEDONC)
Current Status: Open
Phase: II (Cancer Control)
Principal Investigator: Beck, Jill
Eligibility: https://clinicaltrials.gov/study/NCT03213704?term=NCT03213704&rank=1
Summary
To determine the objective response rate (ORR; complete response + partial
response) in pediatric patients treated with JNJ-42756493 (erdafitinib) with
advanced solid tumors (including CNS tumors), non-Hodgkin lymphomas or
histiocytic disorders that harbor genetic alterations in the FGFR1/2/3/4 pathway.